Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email: bcfdn@aol.com  
Bone and Cancer

Clinical Trials

Apthasol (Amlexanox)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved May 1996

Specific Treatments:

canker sores

Therapeutic Areas

General Information

Apthasol has been approved for the treatment of signs and symptoms of canker sores.

Dentists are now able to prescribe the topical oral paste for subjects who have a recurring problem with apthous ulcers. The paste is applied four times a day and may sting or burn upon application. It is not yet known how Apthasol works, although it is thought it inhibits inflammation and offers protection as a wound covering.

Additional Information

Fifteen percent of the worldwide population suffer from canker sores. In the United States, canker sores result in more than 7,000,000 subjects visits to medical practitioners per year. Canker sores are considered a nuisance and painful, but no real threat. Any sore that persists for more than two weeks, especially one that isn't painful, should be examined by your dentist.

 How To Order Publications:
  Glossary
  FAQ

Information About

Clinical Trials



 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 


  Copyright 2011 - The Bone and Cancer Foundation